DBV Technologies S.A. (EPA:DBV)
France · Delayed Price · Currency is EUR 3.805
-0.150 (-3.79%)
At close: Jan 30, 2026
DBV Technologies Market Cap
DBV Technologies has a market cap or net worth of €1.12 billion as of January 30, 2026. Its market cap has increased by 1,142.13% in one year.
Market Cap
1.12B
Enterprise Value
1.07B
Revenue
4.69M
Ranking
n/a
PE Ratio
n/a
Stock Price
€3.81
Market Cap Chart
Since March 29, 2012, DBV Technologies's market cap has increased from 79.23M to 1.12B, an increase of 1,318.06%. That is a compound annual growth rate of 21.10%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 30, 2026 | 1.12B | 65.69% |
| Dec 31, 2025 | 678.09M | 949.56% |
| Dec 31, 2024 | 64.61M | -63.70% |
| Dec 29, 2023 | 177.98M | -39.80% |
| Dec 30, 2022 | 295.62M | 75.76% |
| Dec 31, 2021 | 168.19M | -29.23% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| ABIVAX Société Anonyme | 7.52B |
| Inventiva | 999.10M |
| Nanobiotix | 869.05M |
| MedinCell | 764.01M |
| Valneva SE | 691.93M |
| Genfit | 283.83M |
| Transgene | 251.37M |
| Cellectis | 247.35M |